• Inhibrx Biosciences recently reported positive interim Phase 2 data from the HexAgon study, where its hexavalent OX40 agonist INBRX-106 combined with pembrolizumab produced higher confirmed response rates and more complete responses than pembrolizumab alone in first-line PD-L1 high head and neck cancer patients.
• These data, supported by strong T-cell activation signals and a generally manageable safety profile, have prompted plans for a Phase 3 trial and broader exploration of INBRX-106 across additional cancer settings and combination partners.
• Next, we’ll explore how this early evidence of enhanced response with INBRX-106 plus pembrolizumab shapes Inhibrx Biosciences’ investment narrative.

AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Inhibrx Biosciences' Investment Narrative?

To own Inhibrx Biosciences, you have to believe its single‑domain antibody platform can turn assets like INBRX‑106 and ozekibart into meaningful, approvable therapies before the cash burn, high valuation and financing needs bite too hard. The new HexAgon data strengthen the near‑term clinical catalyst stack: a Phase 3 start for INBRX‑106 in HNSCC, broader INBRX‑106 combinations, and regulatory milestones for ozekibart in chondrosarcoma and colorectal cancer. At the same time, the interim nature of the HexAgon readout, pending progression‑free survival in late 2026, and Inhibrx’s very limited revenue and ongoing losses keep clinical, funding and execution risks front and center. After a very large 1‑year share price move, this update may sharpen, rather than resolve, the debate around risk versus reward.

However, one key funding risk could quickly change how the story looks for shareholders. Our comprehensive valuation report raises the possibility that Inhibrx Biosciences is priced higher than what may be justified by its financials.

Exploring Other Perspectives

The Simply Wall St Community has a single fair value estimate of US$300 per share, underscoring how opinions can cluster even as HexAgon’s interim data raise fresh questions about clinical risk, trial timelines and funding needs.

Explore another fair value estimate on Inhibrx Biosciences - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Inhibrx Biosciences research is our analysis highlighting 2 important warning signs that could impact your investment decision.
• Our free Inhibrx Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Inhibrx Biosciences' overall financial health at a glance.

Curious About Other Options?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.